Imunofan

Imunofan (RDKVYR; arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine) is a synthetic hexapeptide of 836 Da modeled on positions 32-37 of thymopoietin, a 49-amino-acid hormone produced by thymic epithelial cells. The related pentapeptide thymopentin (TP-5, positions 32-36) represents the recognized bioactive core of thymopoietin; Imunofan extends this sequence by one residue and is described by its developer as possessing broader activity. Thymopoietin binds membrane receptors on prothymocytes and mature T cells, coupling to adenylate cyclase in precursor cells and guanylate cyclase in mature T cells, thereby directing differentiation and functional activation of T-lymphocyte subpopulations.

Imunofan's pharmacological profile is described as unfolding in three temporal phases. In the initial phase (onset within 2-3 hours) it is reported to modulate circulating ceruloplasmin and lactoferrin, scavenging reactive oxygen species and inhibiting lipid peroxidation. In an intermediate phase (approximately 7-10 days) it is said to enhance neutrophil and macrophage bactericidal activity and promote B-cell differentiation and antibody production. A longer-term phase (described as lasting up to 4 months) involves normalization of CD4/CD8 T-cell ratios and consolidation of immune memory.

A distinct mechanism reported by Lebedev and Novikov (2006, PMID 17603672) is context-dependent modulation of P-glycoprotein and related multidrug-resistance transport proteins: Imunofan inhibited these proteins during active substrate transport while increasing their activity during latent periods, with inhibitory potency exceeding competitor substrate analogues by more than 1,000-fold in vitro; the effect was dependent on protein kinase C.

• The peptide is described as modulatory rather than simply stimulatory, normalizing abnormal immune parameters bidirectionally. • In aqueous solution, NMR studies identified a predominant conformation stabilized by a salt bridge between the Asp2 side-chain oxygen and the Arg6 NH proton. • Plasma half-life is short: the peptide binds albumin and becomes undetectable in plasma within approximately one hour at 37 degrees C.

Published clinical evidence for Imunofan is predominantly from Russian-language literature produced largely by or affiliated with its developer (Central Research Institute of Epidemiology, Moscow). Independent replication by Western research groups is absent, and most primary sources are not indexed in English-language databases. Randomization and blinding methodology are often unclear or absent from available abstracts. These limitations substantially constrain the conclusions that can be drawn.

A 1996 comparative clinical study (Ter Arkh; PMID 8771665) involving patients with advanced and toxic diphtheria reported that adjuvant intramuscular Imunofan (1 mL of 0.005% solution, approximately 45 mcg, once daily for 8-10 days) was associated with reduced specific complications and a 4.1- to 4.8-fold reduction in mortality. Sample sizes were not reported in the available English abstract.

An experimental study (PMID 11765469, published 2001) tested Imunofan in ocular models: toxicity was assessed in 30 Wistar rats (60 eyes) with no toxic effects observed on intact tissue, and therapeutic efficacy was evaluated in 13 rabbits with herpes simplex keratitis, where subconjunctival Imunofan injections showed advantages over leukocytic interferon instillations.

A 2020 peer-reviewed study in Molecules (PMC7355430; Baeva et al., n of in-vitro replicates variable, in-vivo n = 50 mice total across two strains) found Imunofan stimulated fibroblast proliferation by 20-40% and keratinocyte proliferation by 20-50% in vitro, and improved ear-pinna wound closure by approximately 8% (BALB/c) and 36% (C57BL/6) versus controls at 42 days. No cytotoxicity or basophil activation was detected across seven independent experiments.

A comparative clinical study published in Acta Biomedica Scientifica (n = 39 patients with acute optic neuritis associated with herpesvirus infection; 22 treatment, 17 control) found that daily intramuscular Imunofan 50 mcg for 10 days, added to a standard multi-drug regimen, led to earlier inflammation resolution, 1.3-fold greater visual acuity improvement, and reduced post-neuritic optic-nerve atrophy incidence over 12 months of follow-up.

A conference abstract (PMC4081846) reported positive cytokine and microbiota normalization in 42 frequently ill children with acute respiratory disease treated with Imunofan, without documenting adverse effects.

The 1995 preclinical study (PMID 8664598) examined Imunofan in cyclophosphamide-induced immunosuppression and ecologically-induced immunodeficiency models using BALB/c and C57BL mice, though no English-language abstract is available.

Typical dosage: 1 mg (daily for 10 days).

Russian-approved clinical protocols describe three formulations. Reported doses reflect the manufacturer's labeling and published study protocols; no Western regulatory authority has reviewed or approved these regimens.

Injectable solution (0.005%, 45 mcg/mL), administered intramuscularly or subcutaneously: • Standard adult dose: 45 mcg (1 mL) once daily or every other day • Oncology and pre-surgical protocols: 8-10 injections, beginning before treatment and continuing throughout chemo-radiation therapy • Chronic infectious diseases, hepatitis, and immunodeficiency states: 15-20 injections total • In the diphtheria clinical study (PMID 8771665): 1 mL once daily for 8-10 days • In the optic neuritis clinical study: 50 mcg intramuscularly once daily for 10 days

Rectal suppositories (90-100 mcg each): • One suppository once daily • Oncology: 8-10 suppositories pre-treatment, continuing throughout the treatment period • Other indications: 15-20-day course

Intranasal spray (45-50 mcg per actuation): • One actuation per nostril, twice daily, for 10-15 days • Maximum single dose: 50 mcg; maximum daily dose: 200 mcg

Repeat courses are described as permissible after 1-6 months, guided by immune status monitoring. Pediatric protocols have been reported in Russian literature (age 2 and older for certain formulations) but detailed pediatric dosing data are not available in English-language sources.

This information is provided for educational and reference purposes only and does not constitute medical advice. Imunofan is not approved by the FDA, EMA, or other Western regulatory bodies, and its use outside Russia and certain CIS countries is not sanctioned by any regulatory authority.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Russian clinical protocols describe Imunofan primarily as an adjunct within multimodal treatment regimens rather than as a stand-alone agent. In the published optic neuritis study, Imunofan supplemented a standard regimen including dexamethasone, Emoxypine, Dicynone, Picamilon, and Semax; this was a controlled comparison, but the study is small and the methodology cannot be fully evaluated from available summaries.

In oncology, Russian manufacturer-issued guidelines recommend Imunofan as an immunoprotective adjunct to chemotherapy and radiotherapy, with the stated rationale of preserving lymphocyte and neutrophil counts, reducing oxidative damage from cytotoxic agents, and counteracting P-glycoprotein-mediated drug resistance. No independent randomized controlled trial data support this specific combination in the English-language literature.

Combination with other thymic peptides (thymalin, thymogen, thymosin alpha-1) is mentioned in Russian immunorehabilitation discussions. Imunofan's synthetic, defined structure is cited as an advantage over thymalin (a polypeptide thymic extract) for reproducibility, though no comparative combination studies have been identified in indexed English sources. Any such combination use is anecdotal at this time.

The theoretical interaction between Imunofan and P-glycoprotein substrates (including certain chemotherapeutic drugs and immunosuppressants) requires caution; no formal pharmacokinetic drug-drug interaction studies have been published.

Imunofan is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated

Imunofan's published safety record within Russian clinical literature spanning more than two decades is notable for its paucity of documented serious adverse events. The independence and completeness of post-marketing surveillance underlying this record cannot be verified externally, which limits confidence in the apparent safety profile.

Official Russian labeling identifies the following contraindications: • Hypersensitivity to the active substance • Pregnancy (particularly in the setting of Rh-factor conflict) • Children under 2 years of age (some labeling specifies under 5 years)

The 2020 Molecules cell-culture study (PMC7355430) found no cytotoxicity across a concentration range of 0.1-100 mcg/mL in human fibroblasts, keratinocytes, and adipose-derived stem cells, and no allergic activation in basophil activation tests across seven independent experiments with peripheral blood mononuclear cells. Imunofan was immunologically inert at the concentrations tested in vitro.

Reported adverse effects in clinical use are described as rare and limited to individual intolerance and mild allergic reactions. No cases of overdose have appeared in the published literature. Local injection-site reactions are described as minimal, attributed to the low injection volume and small molecular weight.

The peptide's rapid plasma clearance (albumin binding, undetectable within approximately one hour) suggests limited systemic accumulation after standard doses.

The primary theoretical safety concern is pharmacokinetic interaction via P-glycoprotein inhibition: co-administered drugs that are P-gp substrates (certain chemotherapeutics, immunosuppressants, cardiac glycosides) could have altered exposure. No formal drug interaction studies have been published.

Data on use during lactation are absent. Use in established autoimmune conditions requires caution given the lack of systematic study, even though no exacerbations have been documented in available Russian-language reports. Imunofan has not been assessed by FDA, EMA, or MHRA.